MedPath

NIVAGEN PHARMACEUTICALS, INC.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

2

Active:0
Completed:2

Trial Phases

1 Phases

Phase 2:2

Drug Approvals

48

FDA:48

Drug Approvals

SODIUM BICARBONATE

Approval Date
Mar 8, 2024
FDA

Hydroquinone 4%

Approval Date
Feb 7, 2024
FDA

SUCCINYLCHOLINE CHLORIDE

Approval Date
Feb 7, 2024
FDA

Atenolol

Approval Date
Feb 6, 2024
FDA

ERYTHROMYCIN

Approval Date
Jan 9, 2024
FDA

Erythromycin Ethylsuccinate

Approval Date
Jan 2, 2024
FDA

SILDENAFIL CITRATE

Approval Date
Dec 20, 2023
FDA

Tadalafil

Approval Date
Dec 20, 2023
FDA

Chlorthalidone

Approval Date
Dec 20, 2023
FDA

CELECOXIB

Approval Date
Dec 20, 2023
FDA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 2
2 (100.0%)

Evaluate Safety and Efficacy of 25 mg Hydrocortisone Acetate Suppositories in Treatment of Internal Hemorrhoids

Phase 2
Completed
Conditions
Internal Hemorrhoids
Interventions
Drug: Placebo (Vehicle) Suppository (Nivagen)
First Posted Date
2017-11-08
Last Posted Date
2022-09-13
Lead Sponsor
Nivagen Pharmaceuticals Inc.
Target Recruit Count
103
Registration Number
NCT03335774
Locations
🇮🇳

Clinical Research, Navi Mumbai, Maharashtra, India

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.